Construction and Evaluation of a Novel Recombinant T Cell Epitope-Based Vaccine against Coccidioidomycosis.

Department of Biology and South Texas Center for Emerging Infectious Diseases, University of Texas at San Antonio, San Antonio, Texas, USA.
Infection and immunity (Impact Factor: 4.16). 09/2012; 80(11):3960-74. DOI: 10.1128/IAI.00566-12
Source: PubMed

ABSTRACT Clinical and animal studies of coccidioidomycosis have demonstrated that activated CD4(+) T lymphocytes are essential for protection against this fungal respiratory disease. We previously reported a vaccine against Coccidioides infection which contained three recombinant CD4(+) T cell-reactive proteins and induced a robust, protective immune response in mice. Due to the anticipated high cost of production and clinical assessment of this multivalent vaccine, we generated a single protein which contained immunodominant T cell epitopes of the three polypeptides. Epitopes were initially identified by computational prediction of their ability to bind promiscuously to human major histocompatibility complex class II (MHC II) molecules. Cellular immunoassays confirmed the immunogenicity of the synthesized epitope peptides, while in vitro binding assays revealed a range of peptide affinity for MHC II. A DNA construct was synthesized for bacterial expression of a recombinant protein vaccine which contained five epitopes with the highest affinity for human MHC II, each fused with leader and spacer peptides proposed to optimize epitope processing and presentation to T cell receptors. Recall assays of immune T lymphocytes obtained from human MHC II-expressing HLA-DR4 transgenic mice confirmed that 4 of the 5 epitope peptides were processed. Mice immunized with the epitope-based vaccine admixed with a synthetic oligodeoxynucleotide adjuvant or loaded into yeast glucan particles and then challenged intranasally with Coccidioides showed early lung infiltration of activated T helper-1 (Th1), Th2, and Th17 cells, elevated gamma interferon (IFN-γ) and interleukin (IL)-17 production, significant reduction of fungal burden, and prolongation of survival compared to nonvaccinated mice. This is the first report of an epitope-based vaccine against coccidioidomycosis.

Download full-text


Available from: Gary R Ostroff, Jul 16, 2014
    • "It is possible that the conjugation of WGPs to proteins specific for Coccidioides could improve the effectiveness of the vaccine preparation. Similarly, the use of multivalent epitope constructs specific to Coccidioides delivered in shells of b-glucan have been shown to induce protective cell-mediated responses (Hurtgen et al., 2012; Cole et al., 2013). These data also support the concept of using glycans as carriers of fungal proteins, similar to our own results and those of Torosantucci et al. (2005), which take advantage of the immunostimulatory properties of b-glucan and reduce the need for an adjuvant such as aluminium hydroxide. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We reported yeast-derived whole glucan particles (WGP), with or without conjugation to BSA, used as a vaccine protected against systemic aspergillosis in mice. Here, we examined their utility as a potential vaccine against coccidioidomycosis. WGP was prepared from Saccharomyces cerevisiae; conjugation with BSA (WGP-BSA) was done using 1-cyano-4-dimethylaminopyridinium tetrafluoroborate-mediated conjugation. Heat killed S. cerevisiae (HKY) was used as a positive control vaccine. CD-1 mice were vaccinated with WGP or WGP-BSA, HKY or PBS once weekly beginning 21 days prior to infection. Mice were infected intravenously with arthroconidia of Coccidioides posadasii. In the low mortality study, 50% of PBS-treated controls died. Only WGP-BSA at 0.6 mg/dose induced significant protection compared to PBS treatment. All surviving mice were infected in all three organs examined. Those given WGP-BSA at 0.6 mg/dose had fewer CFU in liver and lungs (P = 0.04), and WGP at 6 mg/dose fewer in lungs (P < 0.02), compared to PBS. In the high mortality study, 90% of PBS mice died. Vaccination with HKY, and WGP or WGP-BSA at 6 or 12 mg/dose significantly prolonged survival (P ≤ 0.05). No surviving mice were free of infection. HKY and WGP-BSA at 12 mg/dose reduced CFU in the liver and lungs (P < 0.05) and WGP-BSA 6 mg/dose reduced CFU in lungs (P < 0.05); unconjugated WGP did not reduce infection. WGP or WGP-BSA acted as a vaccine that protected against mortality caused by coccidioidomycosis. Thus, WGP protection against coccidioidomycosis and aspergillosis provides the basis for development of a panfungal vaccine.
    Journal of Medical Microbiology 07/2015; DOI:10.1099/jmm.0.000138 · 2.27 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: El término inmunoterapia se refiere a cualquier tratamiento que potencie, restablezca o inhiba la respuesta inmune de un paciente. Entre los agentes biológicos utilizados para inducir una inmunomodulación se encuentran anticuerpos monoclonales, citocinas, factores de crecimiento, proteínas de fusión y células previamente activadas. En el contexto de las micosis, la inmunoterapia se puede abordar desde dos puntos de vista, bien sea como un factor de riesgo que predispone al desarrollo de infecciones fúngicas, cuando esta es dirigida a suprimir funciones del sistema inmune, bien como una estrategia terapéutica adyuvante que potencie el tratamiento en las micosis; ó cuando está encaminada a restablecer o mejorar el estado inmunológico del paciente. En esta revisión, se describen algunos de los agentes biológicos más utilizados en la clínica, así como las infecciones fúngicas más frecuentemente asociadas con su uso. Igualmente, se presentan algunas de las estrategias inmunomoduladoras que a la fecha han sido evaluadas en las micosis, con el fin de mejorar la respuesta inmune del hospedero y las cuales se encuentran en diferentes etapas de desarrollo.
    12/2012; 16(Supl 3):73-81. DOI:10.1016/S0123-9392(12)70030-9
  • [Show abstract] [Hide abstract]
    ABSTRACT: Coccidioidomycosis (San Joaquin Valley fever) is a human respiratory disease caused by a soil-borne mold, and is recognized as an intransigent microbial infection by physicians who treat patients with the potentially life-threatening, disseminated form of this mycosis. Epidemiological studies based on surveys of skin-test reactivity of people who reside in the endemic regions of the Southwestern US have shown that at least 150,000 new infections occur annually. The clinical spectrum of coccidioidomycosis ranges from an asymptomatic insult to a severe pulmonary disease in which the pathogen may spread from the lungs to the skin, bones, brain and other body organs. Escalation of symptomatic infections and increased cost of long-term antifungal treatment warrant a concerted effort to develop a vaccine against coccidioidomycosis. This review examines recently reported strategies used to generate such a vaccine and summarizes current understanding of the nature of protective immunity to this formidable disease.
    Current Fungal Infection Reports 12/2012; 6(4):235-244. DOI:10.1007/s12281-012-0105-y
Show more